Abstract
Abstract To support the preclinical development of RP 69698, a novel antagonist of LTB4, a high-performance liquid chromatographic (HPLC) procedure was developed for its determination in plasma. The method involves extraction of RP 69698 from deproteinized plasma with hexane:ethyl acetate under acidic conditions followed by reversed-phase HPLC with detection at 258 nm. The method is rapid, simple, and is applicable to dog, rat, and monkey plasma. Validation studies using dog plasma showed that the values obtained for parameters of linearity, precision, and accuracy were within acceptable limits. Based on analysis of 0.5 ml of plasma, the lower limit of quantitation was determined to be 25 ng/ml. The method has been successfully applied to determine the pharmacokinetic parameters of RP 69698 in the dog following intravenous and intragastric administration. The results of the dog study indicated rapid clearance of the drug from plasma (0.4 L/hr/kg) and limited distribution (volume of distribution at steady state = 0.24 L/kg). When given intragastrically as a solution in PEG 400, absolute bioavailability of the drug was 59Z but when given as an aqueous suspension in 0.5: methylcellulose, the drug was poorly absorbed with absolute bioavailability estimated to be about 6%.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
